WO2001035093A1 - Methode de detection de la mort cellulaire, et reactif de detection - Google Patents
Methode de detection de la mort cellulaire, et reactif de detection Download PDFInfo
- Publication number
- WO2001035093A1 WO2001035093A1 PCT/JP2000/007838 JP0007838W WO0135093A1 WO 2001035093 A1 WO2001035093 A1 WO 2001035093A1 JP 0007838 W JP0007838 W JP 0007838W WO 0135093 A1 WO0135093 A1 WO 0135093A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cytochrome
- cell death
- encephalopathy
- antibody
- diagnosis
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/795—Porphyrin- or corrin-ring-containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Definitions
- the present invention relates to a method and a reagent for detecting cell death.
- GVHD graft-versus-host reaction disease
- HPS hemophagocytic syndrome
- Morphological method DNA fragmentation that specifically occurs in apoptosis is detected by staining method. Chromatin condensation determination method and morphological change specific to apoptosis are detected by electron microscopy or cell size measurement. Have been.
- Histochemical method A method is used in which labeled nucleotides are bound to the ends of the MA fragments and detected by fluorescence microscopy. Alternatively, flow cytometry is used to measure the amount of intracellular substances in individual cells. Using the bird method has also been practiced.
- Biochemical method The method of detecting MA ladder by agarose gel electrophoresis is used, and it is currently the most reliable method for proving apoptosis. It is said that there is a problem in sensitivity and quantification if the proportion of apoptotic cells is not high because of extraction.
- Immunochemical method An enzyme-linked immunosorbent assay (ELISA) (cell detection ELI SA: Boehringer Mannheim, Domestic Chemistry) has been developed to detect histone-binding DNA fragments (mononucleosomes or oligonucleosomes).
- An object of the present invention is to develop a simple method and reagent excellent in sensitivity and quantification for detecting apoptosis occurring in a living body.
- Cytochrome C is known as a crucial protein of the electron transport system in mitochondria, but when cells are exposed to a stimulus that triggers apoptosis and become apoptotic, cytochrome C in mitochondria is released. It has been reported to be rapidly released into the cytosol (Dinsdale, D. et al., American J. Pathol. 155: 607-18, 1999). Cytosol C has been reported to be involved in the activation of caspase-3, a key factor in apoptosis, and that the addition of cytochrome C is related to the progression of apoptosis ( Medina, V. et al., Cancer Research 57: 3697-707, 1999).
- the present inventors thought that if apoptosis occurs in a living body, cytochrome C released from mitochondria could be measured in blood.
- cytochrome C released from mitochondria could be measured in blood.
- ELISA ELISA that measures cytochrome C, and found that it has a strong correlation with the amount of cytochrome C in blood, VHD, HPS, acute lymphocytic leukemia, and the progression of influenza encephalopathy. It has arrived.
- the present invention provides a method for detecting cell death occurring in a living body by quantifying cytochrome C in a body fluid as described below, and a method for measuring cytochrome C that can be used in the method.
- a method for detecting cell death which comprises quantifying cytochrome C in a body fluid and detecting cell death based on the quantified value.
- a reagent for measuring cytochrome C in a body fluid by the Sandwich method which comprises an antibody to cytochrome C as a component.
- Viral encephalitis ⁇ The reagent for measuring cytochrome C according to (4), which is a diagnostic river for encephalopathy.
- FIG. 1 shows changes in LDH, AST, ALT, ferritin and cytochrome C (Cyto-C) levels in the serum of HPS patients.
- Figure 2 shows the amount of cytochrome C in the serum of influenza patients with high fever, febrile seizures and encephalitis / encephalopathy.
- FIG. 3 shows changes in the values of G0T, LDH and cytochrome C in the blood of a patient who developed influenza encephalopathy.
- Figure 4 shows the amount of various cytokines in the serum of influenza patients with high fever, febrile seizures, encephalitis and encephalopathy.
- cytochrome C translocated from the mitochondria to the cytoplasm in response to the apoptotic signal and released as a result of cell death due to disruption of the cell membrane.
- cytochrome C released outside cells due to cell death can be detected by quantification of cytochrome C in a body fluid, for example, blood, and occurs in a living body by quantifying cytochrome C in a body fluid. See if you can detect cell death It is based on what was issued. Therefore, any method for detecting cell death by quantifying cytochrome C in a body fluid is included in the present invention.
- cell death mainly refers to apoptosis, but it is generally not easy to specify that cell death occurring in a living body is apoptosis.
- Cell death accompanied by an increase is included in the cell death in the present invention.
- the body fluid means blood, plasma, serum, cerebrospinal fluid, etc. collected from a living body.
- Methods for measuring cytochrome C include an immunochemical method, a method using ii electrophoresis, and a method using chromatography.
- Examples of the method by electrophoresis include a method in which polyacrylamide gel electrophoresis is performed to detect cytochrome C as a band, and a method in which peaks are detected in capillary electrophoresis.
- As a method based on chromatography there is a method of detecting as a peak by high performance liquid chromatography. In some cases, in order to increase the sensitivity, fluorescent labeling is allowed, but the present invention is not limited to these examples.
- an immunochemical method is preferable in terms of sensitivity and simplicity.
- the immunochemical method is a method for quantifying cytochrome c by supplying an antibody against cytochrome c.
- immunochemical methods such as a competitive method for labeling cytochrome c, a sandwich method for labeling antibodies, and a latex bead method for observing aggregation of antibody-coated beads.
- the method used is included in a preferred embodiment of the present invention.
- the antibody may be a monoclonal antibody or a polyclonal antibody.
- labeling methods such as labeling with a radioisotope, labeling with a compound that emits electrochemiluminescence, fluorescent labeling, enzyme labeling, and labeling with virgin, but the present invention is limited to these examples. Not a thing.
- the sandwich method is described below step by step.
- the beads may be microbeads, and in that case, magnetic microbeads are preferable. Immobilization is It may be bonded by a covalent bond or a non-covalent bond. Usually, a blocking operation is performed using a protein such as serum albumin (BSA) or casein, or a surfactant such as Tween 20 to block a non-specific binding site on the bead or the cup.
- BSA serum albumin
- Tween 20 a surfactant
- cytochrome C is also diluted and added.
- a buffer containing a surfactant such as Tween 20 If possible, wash the beads or forceps with a buffer containing a surfactant such as Tween 20, and measure according to the labeling method. For example, radioactivity is measured for a radioactive label, and enzyme activity is measured for an enzyme label. If the label is a biotinylated label, add labeled avidin and measure according to the label.
- cytochrome C in the sample is quantified.
- cytochrome C If the quantitative value of cytochrome C is higher than the normal value, cell death can be detected.
- the present invention relates to a method for measuring cytochrome C, which comprises quantifying cytochrome C in a body fluid by a sandwich method.
- the sandwich method is an immunochemical method such as ELISA that utilizes a state in which an antigen is sandwiched between an immobilized antibody and a labeled antibody.
- the dot blot method As a method for measuring cytochrome C by an immunochemical method, the dot blot method is widely used (Souichi A. et. Al., J. Biological Chem. 273: 1989 2-4, 1998). However, this method can measure cytochrome C in cell homogenate with high content of cytochrome C and low protein concentration, but highly sensitive quantification of cytochrome C in body fluid with low content of cytochrome C and high protein concentration Was unsuitable for doing so.
- the present invention determines cytochrome C in body fluids with high protein concentration with high sensitivity. They applied the sandwich method, ELISA, to measure the amount of cytochrome C in body fluids, and found that the amount could be as small as released by cell death in vivo.
- the present invention relates to a cytochrome C measurement reagent for quantitatively determining cytochrome C in a body fluid by a sandwich method, which comprises an antibody against cytochrome C as a component.
- the measurement reagent may have the same configuration as the reagent (kit) used in the ordinary sandwich method except that an anti-cytochrome C antibody is used as the antibody.
- measurement reagents for measuring cytochrome C by the sandwich method include, for example, 1) solid phase of anti-cytochrome C antibody coat such as anti-cytochrome C antibody coat cup, anti-cytochrome C antibody-coated beads, and 2) labeled anti-cytochrome C antibody. , 3) Cytochrome C standard solution of known concentration, 4) Diluent, 5) Wash solution.
- it is an enzyme label, it may contain 6) a coloring substance and 7) a reaction stop solution.
- the method and assay reagent for measuring cytochrome C disclosed in the present invention enables detection of cell death. Therefore, it is possible to provide an index for diagnosis or follow-up of various diseases associated with apoptosis. Accordingly, there is provided a method and a reagent for measuring cytochrome C, which are useful for diagnosing a disease associated with cell death detection apoptosis.
- examples of the disease accompanied by apoptosis include the following examples.
- VAHS virus-associated hemophagocytic syndrome
- HCV HCV, HIV, Influenza virus
- Leukemia for example, acute lymphocytic leukemia.
- SIRS Systemic Inflammatory Response Syndrome
- Encephalitis' encephalopathy is a disease that is caused by a viral infection and is serious and easily persists. Encephalitis caused by influenza virus in particular.Encephalopathy accounts for a large proportion of deaths due to influenza, but it is difficult to distinguish it from febrile seizures.Therefore, there is a need for an accurate early diagnosis method for appropriate treatment. I have. According to the measuring method and the measuring agent of the present invention, accurate early diagnosis can be performed.
- cytochrome C By measuring cytochrome C in body fluids, it is possible to measure the progress of cell death in vivo and monitor the progress of these diseases. Especially in GVHD, hemophagocytic syndrome (HPS), especially virus-associated hemophagocytic syndrome (VAHS), acute lymphocytic leukemia, and influenza encephalitis / encephalopathy, it is useful to quantify cytochrome C to understand the pathology.
- HPS hemophagocytic syndrome
- VAHS virus-associated hemophagocytic syndrome
- acute lymphocytic leukemia e.g., acute lymphocytic leukemia
- influenza encephalitis / encephalopathy it is useful to quantify cytochrome C to understand the pathology.
- Cytochrome C in body fluids is a good indicator of cell death occurring in the body and can be a useful indicator for quickly and accurately knowing the disease state.
- the method for measuring cytochrome C is as follows.
- Rats were immunized with rat cytochrome C (Sigma) and Obtain antiserum. Add ammonium sulfate to the antiserum to a final concentration of 2 M, and stir at room temperature (20-30 ° C) for 5 hours. Centrifuge the stirred solution at 10,000 rpm for 30 minutes, discard the supernatant, dissolve the precipitate in 0.1 M phosphate buffer pH 7.2, and dialyze against the same buffer. The dialyzed solution is applied to a carrier column obtained by combining CNBr-Sepharose 4B (Pharmacia) with cytochrome C.
- the anti-cytochrome C antibody is eluted with 0.1 M guanidine hydrochloride, and the eluate is diluted with 0.01 M squirrel-HCl buffer pH 7.5 containing 0.15 M NaCl. Dialyzed to obtain a purified antibody (IgG).
- the purified IgG is dialyzed against 0.1 M acetate buffer pH 4.2. Add pepsin (Sigma) to the dialyzed IgG solution at a mass concentration ratio of 20: 1, and react at 37 ° C for 16 hours. The pH of the solution after the reaction was adjusted to 7.5 with 1 N ⁇ 011, and then equilibrated with 0.01 M Tris-HCl buffer pH 7.5 containing 0.15 M NaCl using an 86 11 &(; 1 S-200 (Pharmacia) column. Perform gel filtration Collect a single peak of the gel-filtered fraction, concentrate and concentrate as anti-cytochrome C antibody F (ab ') 2 solution.
- HRP horseradish peroxidase
- Toyobo horseradish peroxidase
- anti-cytochrome 0 antibodies were dialyzed against 0.1 Micromax carbonate buffer pH 9.5 1 ⁇ (& 1 3 ') ;; solution (4 mg / ml) 1 ml was added, 2 at room temperature (20 to 30 ° C) Stir for hours. Add 50 1 of sodium borohydride solution adjusted to 4 mg / ml, stir at 4 ° C for 2 hours, and store still for 16 hours.
- This solution is dialyzed against phosphate buffer pH 7.2 containing 0.15 M NaCl, and then subjected to gel filtration using a Sephacryl S-200 (Pharmacia) column.
- Rat cytochrome C (Sigma) was added to 1 BSA, 0.01 M EDTA 2Na, 0.1% NaN 3 ,
- Example 2 Determination of cytochrome C in serum of patients with GVHD, HPS and acute lymphocytic leukemia Using the ELISA system of cytochrome C described in Example 1, GVHD, HPS and acute lymphoblastic leukemia patients and healthy The amount of cytochrome C in human serum was measured.
- Fig. 1 shows LDH, AST, ALT, ferritin and cytochrome C in serum of HPS patients. The transition of the value was shown. Cytochrome C is almost correlated with the LDH value, and changes prior to LDH, and is considered to be useful as an index to detect changes in the disease state sharply.
- Example 3 Quantification of cytochrome C in serum of patients with influenza encephalitis and encephalopathy Using the ELISA system described in Example 1, among influenza patients, in serum of patients with high fever, febrile convulsion and encephalitis and encephalopathy was measured for the amount of cytochrome C.
- Figure 2 shows the results, including the case of performing multiple measurements in one case. In cases with encephalitis and encephalopathy, all 27 samples (8 cases) showed high values of 5 ng / ml or more, and among them, 17 samples showed high values of 30 ng / ml or more. The prognosis was poor for those who had high levels of cytochrome C in the blood.
- FIG. 3 shows changes in blood G0T, LDH and cytochrome C values of patients who developed influenza encephalopathy. Cytochrome C rises and falls before LDH, indicating that cytochrome C is Arikawa as a leading indicator, reflecting the pathology of influenza encephalopathy.
- Example 4 Influenza encephalitis ⁇ Various cytokine concentrations in serum of encephalopathy patients E-selectin, soluble thrombomodul in serum of influenza patients with high fever, febrile seizures and encephalopathy in)
- E-selectin is sE-selectin ELISA kit (version 2, manufactured by Bender med systems)
- sTM is TM test (manufactured by Teij in Diagnostics)
- TNF is human TNF-cysteine screen immunoassay kit (Bioscurce International)
- Fas was measured using an sFas ELISA kit
- FasL was measured using an sFas ligand ELISA kit (both manufactured by Medical and Biological Laboratories)
- cytochrome C was measured using the ELISA system described in Example 1.
- cytochrome C As shown in Fig. 4, all cytokines show high levels in serum from encephalitis and encephalopathy patients. Although cytochrome C increased most significantly in encephalitis' encephalopathy, it was shown that cytochrome C was the most suitable for differentiation between encephalitis and encephalopathy.
- the present invention provides an immunochemical method suitable for quantifying cytochrome C in a body fluid.
- cytochrome C has been shown to be a good indicator of cell death occurring in vivo and a useful indicator for quickly and accurately knowing the disease state. It is useful for the diagnosis and follow-up of diseases related to the progression of the disease, especially GVHD, HPS, acute lymphocytic leukemia, influenza encephalitis and encephalopathy.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60035286T DE60035286T2 (de) | 1999-11-08 | 2000-11-08 | Verfahren zum Nachweis von Zelltod mittels Cytochrom C. |
EP00974820A EP1229328B1 (en) | 1999-11-08 | 2000-11-08 | Method of detecting cell death using cytochrome C. |
US10/129,644 US7070924B1 (en) | 1999-11-08 | 2000-11-08 | Method of detecting cell death and detection reagent |
JP2001536573A JP3869722B2 (ja) | 1999-11-08 | 2000-11-08 | 細胞死の検出方法及び検出試薬 |
US11/402,538 US20060183176A1 (en) | 1999-11-08 | 2006-04-12 | Method and reagent for detecting cell death |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP31647599 | 1999-11-08 | ||
JP11/316475 | 1999-11-08 | ||
JP2000/274257 | 2000-09-11 | ||
JP2000274257 | 2000-09-11 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/402,538 Division US20060183176A1 (en) | 1999-11-08 | 2006-04-12 | Method and reagent for detecting cell death |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001035093A1 true WO2001035093A1 (fr) | 2001-05-17 |
Family
ID=26568676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/007838 WO2001035093A1 (fr) | 1999-11-08 | 2000-11-08 | Methode de detection de la mort cellulaire, et reactif de detection |
Country Status (7)
Country | Link |
---|---|
US (2) | US7070924B1 (ja) |
EP (1) | EP1229328B1 (ja) |
JP (1) | JP3869722B2 (ja) |
AT (1) | ATE365327T1 (ja) |
DE (1) | DE60035286T2 (ja) |
ES (1) | ES2288877T3 (ja) |
WO (1) | WO2001035093A1 (ja) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1516186A1 (en) * | 2002-06-26 | 2005-03-23 | University of Louisville Research Foundation, Inc. | A method for the detection of apoptosis |
WO2006112445A1 (ja) | 2005-04-15 | 2006-10-26 | Eisai R & D Management Co., Ltd. | チトクロムcの免疫化学的測定方法及び測定キット |
WO2007116975A1 (ja) | 2006-04-06 | 2007-10-18 | Eisai R & D Management Co., Ltd. | チトクロムcの定量による非アルコール性脂肪性肝炎の非侵襲的な検査方法及び検査キット |
US7357928B2 (en) | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
US7541150B2 (en) | 2002-04-08 | 2009-06-02 | University Of Louisville Research Foundation, Inc | Method for the diagnosis and prognosis of malignant diseases |
JP2009244257A (ja) * | 2008-03-10 | 2009-10-22 | Eisai R & D Management Co Ltd | 癌の浸潤と転移の検査方法及び検査用試薬 |
JP2009264846A (ja) * | 2008-04-23 | 2009-11-12 | Nippon Medical School | 脳症由来痙攣と発熱由来熱性痙攣の鑑別方法 |
JP2012501457A (ja) * | 2008-08-29 | 2012-01-19 | アスチュート メディカル,インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法および組成物 |
US9260517B2 (en) | 2009-11-17 | 2016-02-16 | Musc Foundation For Research Development | Human monoclonal antibodies to human nucleolin |
US9452219B2 (en) | 2011-06-02 | 2016-09-27 | University Of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles |
US10857237B2 (en) | 2015-05-05 | 2020-12-08 | University Of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and MRI and/or X-ray contrast agents |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060263809A1 (en) * | 2005-04-05 | 2006-11-23 | The Rgents Of The University Of California | Method for sensitive measure of low level apoptosis in cells |
JP6074846B2 (ja) * | 2010-12-16 | 2017-02-08 | 国立研究開発法人産業技術総合研究所 | 髄液型糖タンパク質の富化及び分離方法、並びにその方法を用いた中枢神経系疾患用マーカーの探索方法及び中枢神経系疾患用マーカー |
US10012648B2 (en) | 2014-06-03 | 2018-07-03 | Yale University | Plasma cytochrome C as a biomarker for mitochondrial toxicity during antiretroviral therapy |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03257367A (ja) * | 1990-03-08 | 1991-11-15 | Morinaga & Co Ltd | 血清診断法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR910017189A (ko) * | 1990-03-08 | 1991-11-05 | 마쯔자끼 아끼오 | 암의 혈청진단법 및 이에 사용되는 키트(kit) |
US5780237A (en) * | 1994-10-12 | 1998-07-14 | Cell Therapeutics, Inc. | Sepsis, adult respiratory distress syndrome, and systemic inflammatory response syndrome diagnostic |
WO1998002579A1 (en) | 1996-07-12 | 1998-01-22 | Emory University | Regulation of apoptosis and in vitro model for studies thereof |
DE60115453T2 (de) * | 2000-07-21 | 2006-08-24 | Evotec Ag | Verfahren zur detektion der apoptose durch ermittlung von cytochrom c als apoptosespezifischem marker, der durch zelluläre ausschüttungsvorgänge ins extrazelluläre medium abgegeben wird |
US7138239B2 (en) * | 2001-05-09 | 2006-11-21 | Eisai Co., Ltd. | Method and reagent for testing for multiple organ failure in SIRS by cytochrome C measurement |
JP2005147783A (ja) * | 2003-11-13 | 2005-06-09 | Eisai Co Ltd | チトクロムcによる細胞死の診断薬 |
-
2000
- 2000-11-08 DE DE60035286T patent/DE60035286T2/de not_active Expired - Lifetime
- 2000-11-08 EP EP00974820A patent/EP1229328B1/en not_active Expired - Lifetime
- 2000-11-08 AT AT00974820T patent/ATE365327T1/de not_active IP Right Cessation
- 2000-11-08 US US10/129,644 patent/US7070924B1/en not_active Expired - Lifetime
- 2000-11-08 ES ES00974820T patent/ES2288877T3/es not_active Expired - Lifetime
- 2000-11-08 WO PCT/JP2000/007838 patent/WO2001035093A1/ja active IP Right Grant
- 2000-11-08 JP JP2001536573A patent/JP3869722B2/ja not_active Expired - Fee Related
-
2006
- 2006-04-12 US US11/402,538 patent/US20060183176A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03257367A (ja) * | 1990-03-08 | 1991-11-15 | Morinaga & Co Ltd | 血清診断法 |
Non-Patent Citations (2)
Title |
---|
BIOLOGICAL ABSTRACTS, 1999, Philadelphia, PA, US; abstract no. 199900013224, M. FUJIMURA ET AL.: "Cytosolic redistribution of cytochrome C after transient focal cerebral ischemia in rats" XP002935895 * |
J. CEREBRAL BLOOD FLOW AND METABOLISM, vol. 18, no. 11, 1998, pages 1239 - 1247 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8586717B2 (en) | 2002-04-08 | 2013-11-19 | University Of Louisville Research Foundation, Inc | Method for the diagnosis and prognosis of malignant diseases |
US8029784B2 (en) | 2002-04-08 | 2011-10-04 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
US7357928B2 (en) | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
US7541150B2 (en) | 2002-04-08 | 2009-06-02 | University Of Louisville Research Foundation, Inc | Method for the diagnosis and prognosis of malignant diseases |
EP1516186A4 (en) * | 2002-06-26 | 2006-11-22 | Univ Louisville Res Found | PROCEDURE FOR APOPTOSE DETECTION |
EP1516186A1 (en) * | 2002-06-26 | 2005-03-23 | University of Louisville Research Foundation, Inc. | A method for the detection of apoptosis |
JP4896022B2 (ja) * | 2005-04-15 | 2012-03-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | チトクロムcの免疫化学的測定方法及び測定キット |
US7892757B2 (en) | 2005-04-15 | 2011-02-22 | Eisai R&D Management Co., Ltd. | Immunochemical determination method and determination reagent for cytochrome c |
WO2006112445A1 (ja) | 2005-04-15 | 2006-10-26 | Eisai R & D Management Co., Ltd. | チトクロムcの免疫化学的測定方法及び測定キット |
WO2007116975A1 (ja) | 2006-04-06 | 2007-10-18 | Eisai R & D Management Co., Ltd. | チトクロムcの定量による非アルコール性脂肪性肝炎の非侵襲的な検査方法及び検査キット |
JP2009244257A (ja) * | 2008-03-10 | 2009-10-22 | Eisai R & D Management Co Ltd | 癌の浸潤と転移の検査方法及び検査用試薬 |
JP2009264846A (ja) * | 2008-04-23 | 2009-11-12 | Nippon Medical School | 脳症由来痙攣と発熱由来熱性痙攣の鑑別方法 |
JP2016053587A (ja) * | 2008-08-29 | 2016-04-14 | アスチュート メディカル,インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法および組成物 |
JP2012501457A (ja) * | 2008-08-29 | 2012-01-19 | アスチュート メディカル,インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法および組成物 |
US9260517B2 (en) | 2009-11-17 | 2016-02-16 | Musc Foundation For Research Development | Human monoclonal antibodies to human nucleolin |
US10385128B2 (en) | 2009-11-17 | 2019-08-20 | Musc Foundation For Research Development | Nucleolin antibodies |
US9452219B2 (en) | 2011-06-02 | 2016-09-27 | University Of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles |
US11344633B2 (en) | 2011-06-02 | 2022-05-31 | University Of Louisville Research Foundation, Inc | Anti-nucleolin agent-conjugated nanoparticles |
US10857237B2 (en) | 2015-05-05 | 2020-12-08 | University Of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and MRI and/or X-ray contrast agents |
Also Published As
Publication number | Publication date |
---|---|
EP1229328B1 (en) | 2007-06-20 |
DE60035286D1 (de) | 2007-08-02 |
JP3869722B2 (ja) | 2007-01-17 |
DE60035286T2 (de) | 2008-02-21 |
US20060183176A1 (en) | 2006-08-17 |
EP1229328A4 (en) | 2005-02-23 |
ATE365327T1 (de) | 2007-07-15 |
US7070924B1 (en) | 2006-07-04 |
ES2288877T3 (es) | 2008-02-01 |
EP1229328A1 (en) | 2002-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060183176A1 (en) | Method and reagent for detecting cell death | |
Amanzada et al. | Identification of CD68+ neutrophil granulocytes in in vitro model of acute inflammation and inflammatory bowel disease | |
US6916626B1 (en) | Detection of Candida | |
Nakagawa et al. | Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma. | |
WO2005080982A1 (ja) | A型及びb型急性大動脈解離と急性心筋梗塞の鑑別方法及び鑑別用キット | |
JP4514791B2 (ja) | 肝線維症の診断方法 | |
Omran et al. | Enhanced liver fibrosis test using ELISA assay accurately discriminates advanced stage of liver fibrosis as determined by transient elastography fibroscan in treatment naïve chronic HCV patients | |
JP2911602B2 (ja) | 診断のための補助物としての酵素指標の測定 | |
EP1975614A1 (en) | Method for prediction of prognosis of acute coronary syndrome | |
JP2009536327A (ja) | 薬剤誘導肝臓損傷及び中毒性物質誘導肝臓損傷の同定及び早期同定並びに治療の同時観察のためのinvitro方法 | |
TW201930881A (zh) | 大腸直腸腺瘤之檢測及治療方法 | |
WO2014114300A1 (en) | Novel disease-marker | |
JP5176239B2 (ja) | チトクロムcの定量による非アルコール性脂肪性肝炎の非侵襲的な検査方法及び検査キット | |
EP3879270A1 (en) | Method for detecting viral liver cancer | |
WO2012086346A1 (ja) | 抑制性補助刺激分子に対する抗体をマーカーとする慢性炎症性疾患の検査方法 | |
JP3895262B2 (ja) | C型肝炎罹患検査方法 | |
JP3896303B2 (ja) | チトクロムc測定によるsirsにおける多臓器不全の検査試薬 | |
JP5663494B2 (ja) | 尿検体中のサブスタンスpの測定方法 | |
EP4080214A1 (en) | Rapid detection method for anti-drug antibody | |
EP4075138A1 (en) | Composition employing wasf2 autoantibody for early diagnosis of hepatocellular carcinoma | |
JP2012225941A (ja) | 劇症1型糖尿病の検査方法及び検査試薬 | |
Lei et al. | Evaluation of the Diagnostic Accuracy of the HBsAg Rapid Test for Hepatitis B Virus Infection | |
JP2022022635A (ja) | 自己免疫性肝炎を判定するためのバイオマーカー | |
JP2005121441A (ja) | Muc−1定量による間質性肺炎発症を予測する検査方法 | |
JP5152766B2 (ja) | 癌の浸潤と転移の検査方法及び検査用試薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 536573 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10129644 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000974820 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000974820 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000974820 Country of ref document: EP |